|
IgG-Specific Enzymes with Reduced Residual Glycan Hydrolysis
Application
Novel enzymes for IgG-specific glycosynthesis.
Key Benefits
Nearly full glycosylation of IgG antibodies.
Improved antibody-mediated effector function properties.
No measurable residual hydrolysis activity.
Market Summary
The global monoclonal antibodies market is experiencing significant growth due to the rising prevalence of chronic...
Published: 4/3/2025
Contributor(s): Eric J. Sundberg, Jonathan Du, Tala Azzam
|
|
Anti-Green Fluorescent Protein Antibodies
Applications
Western Blot
Immunocytochemistry
Immunohistochemistry
Specificity
Vertebrates
Subtype
Chicken Polyclonal
Immunogen
His-tagged green fluorescent protein of the bioluminescent hydrozoan jellyfish (Aequorea Victoria).
Technical Summary
Drs. Tomasiewicz, Wood, & Flaherty have created a polyclonal anti- green fluorescent...
Published: 2/13/2025
Contributor(s): Henry Tomasiewicz, John Wood, Denise Flaherty
|
|
EF-Tu Targeting Antibody for Infection Treatment
Application
Therapeutic monoclonal antibodies directed to Elongation Factor-Tu (EF-Tu) for the treatment of infections.
Key Benefits
An antibody that targets the protein EF-Tu, which is present on many types of bacteria involved in life-threatening infections.
A research-grade antibody has been developed with animal data showing the ability to...
Published: 2/13/2025
Contributor(s): Joanna Goldberg, Dina Moustafa
|
|
SARS-CoV-2 Neutralizing Human Monoclonal Antibodies
Application
Monoclonal antibodies to SARS-CoV2 for use in COVID-19 diagnostics and therapeutics.
Key Benefits
Demonstrably neutralizing, important for therapeutic mAbs.
Most bind both RBG and stalk portion of spike protein, useful in case SARS-CoV2 strains develop variation in RBD.
Market Summary
Coronavirus (COVID-19) is an infectious...
Published: 4/3/2025
Contributor(s): Jens Wrammert, Carl Davis, Mehul Suthar, Robert Kauffman
|
|
BG505 SOSIP Vaccine Elicited Neutralizing Monoclonal Antibodies for HIV
Application
ELISA
Western Blot
Immunohistochemistry
Specficity
HIV-1 BG505 Env protein (clone name: YRK01, YRK02).
Subtype
Monoclonal antibody.
Immunogen
HIV-1 BG505 SOSIP Env trimer.
Technical Summary
HIV-1 envelope glycoprotein (Env) is a membrane protein complex involved in receptor recognition and viral fusion with CD4+ T cells...
Published: 2/13/2025
Contributor(s): Cynthia Derdeyn, Tysheena Charles
|
|
Galectin-9 Directed CAR T-cells for Overcoming Resistance to Chemotherapy in Hematological Malignancies
Application
Anti-human Galectin-9-directed chimeric antigen receptor (CAR) T-cells for treatment of hematological malignancies (B-ALL, T-ALL, and DLBCL) in normal, overweight, and obese patients.
Key Benefits
Can be used as a stand-alone or in-combination product to treat patients with hematological malignancies, particularly overweight and obese...
Published: 2/13/2025
Contributor(s): Curtis Henry, Miyoung (Mi-Young) Lee, Sunil Raikar, Jamie Hamilton, Anthony Ross
|
|
Trimeric Immunogen for HIV-1 Vaccination
Application
Trimeric gp120 immunogen that induces broadly cross-reactive V1V2-antibodies for HIV-1 vaccine.
Key Benefits
Possible oral administration.
Broadly cross-reactive against HIV-1 panel.
Promotes antibody responses as both a primary immunogen and boosting immunogen.
Market Summary
Antiretroviral therapy (ART) has dramatically prolonged...
Published: 2/28/2025
Contributor(s): Rama Rao Amara, Andrew Jones, Raghavan Varadarajan, Sannula Kesavardhana
|
|
Antibody Therapy for Varicella Zoster Virus
Application
Human monoclonal antibodies for the treatment of varicella zoster virus (VZV).
Key Benefits
Human monoclonal antibodies can limit the spread of VZV.
gH-specific antibodies are complement-independent.
Market Summary
Varicella Zoster Virus (VZV) causes varicella, more commonly known as chickenpox. Once the illness resolves, the virus...
Published: 3/6/2025
Contributor(s): Rafi Ahmed, Nicole Sullivan
|
|
Promising Antibodies Target Virus Glycoprotein for Vaccination and Therapy
ApplicationAntibodies that bind and neutralize Ebola virus glycoprotein (GP) for use in vaccination or treatment of Ebola virus disease.Key BenefitsHigher binding affinity for Ebola virus GP than closest competitor.Can be used prophylactically or for treatment of Ebola virus disease.Market SummaryThe Ebola virus is an RNA virus with a membrane composed...
Published: 4/3/2025
Contributor(s): Rafi Ahmed, Carl Davis, Erica Ollmann Saphire
|
|
Specialized Cell Culturing Media for Enhanced Antibody Secretion and Plasma Cell Survival
Application
Cell culture media that promotes the survival of human plasma cells and enables immunoglobin (Ig) secretion from such plasma cells.
Key Benefits
Facilitates the isolation of antibody-secreting cells (ASCs) found in blood after antigen exposure, which can be used to identify an active antigen or pathogen causing illness.
Composed of...
Published: 2/13/2025
Contributor(s): Frances Eun-Hyung Lee, Ignacio (Inaki) Sanz, Doan Nguyen
|
